MapLight (MPLT) CSO Lillie Woodruff Receives RSU Award

What Happened
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), was granted a total of 39,125 restricted stock units (RSUs) on August 17, 2026 — recorded as two awards: 7,730 RSUs and 31,395 RSUs, each at $0.00 (no cash paid). These awards are reported as grant/award transactions (code A) and represent a contingent right to receive shares of MapLight common stock if and when the RSUs vest.

Key Details

• Transaction date: August 17, 2026; Form 4 filed August 19, 2026 (appears timely).
• Awards: 7,730 RSUs (A) and 31,395 RSUs (A, derivative) — total 39,125 RSUs; price reported $0.00.
• Vesting for these RSUs (Footnotes): F1 — 1/4 vest on July 1, 2027, then 1/16 vest each Oct 1, Jan 1, Apr 1 and Jul 1 thereafter, subject to continued service. F2 — each RSU equals the contingent right to receive one share of common stock.
• Footnote F3 outlines a separate option vesting schedule (1/4 on July 1, 2027, then 1/48 monthly); filing includes this note but the reported August 17 transactions are RSU grants.
• Shares owned after the transaction: not specified in the provided filing details.

Context
This was an equity grant (compensation award), not a market purchase or sale. RSU grants are common for executive compensation and only become shares if vesting conditions are met; they do not by themselves indicate immediate buying or selling of shares. The filing shows standard vesting tied to continued service, with the first vesting tranche on July 1, 2027.